Paper Details

  1. Home
  2. Paper Details

Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.

Author: BennettNathan, FrenklTara L, GreenStuart, MitchesonHenry D, MuddPaul N, MuldowneyKaren, PintoCathy A, RochaBeatriz de A, SamantaSuvajit

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Once-daily vibegron 50 and 100 mg improved overactive bladder (OAB) symptoms and was well tolerated alone or with tolterodine.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Antimuscarinics have shown modest efficacy with unwanted side effects in patients with overactive bladder (OAB). Efficacy of vibegron, a new β3-adrenergic receptor agonist, for OAB is unknown. OBJECTIVE: To evaluate the efficacy of once-daily oral vibegron in OAB patients (primary), and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eururo.2018.10.006

データ提供：米国国立医学図書館（NLM）

Vibegron: A Potential Oasis for Overactive Bladder

Overactive bladder, a common and often embarrassing condition, can create a desert of discomfort and social anxiety for those who suffer from it. This study delves into the potential benefits of vibegron, a new medication that targets the β3-adrenergic receptor, as a treatment for overactive bladder, seeking to discover a refreshing oasis in the desert of symptoms.

A New Path: Vibegron Shows Promise for Overactive Bladder

The study, a randomized, double-blind, placebo-controlled trial, found that vibegron was effective in reducing overactive bladder symptoms, including urinary frequency, urgency, and incontinence. This suggests that vibegron could offer a new and potentially more effective path for managing overactive bladder, providing relief for those who have not found success with traditional treatments. It's like discovering a hidden spring in the desert, offering a fresh source of comfort and control.

Navigating the Desert: Finding the Right Treatment

While vibegron shows promise, it's important to remember that each individual's experience with overactive bladder is unique, just as each desert landscape is distinct. The study also found that vibegron was well-tolerated, with fewer side effects compared to some traditional medications. This suggests that vibegron could offer a gentler, more comfortable path through the desert of overactive bladder symptoms.

Dr. Camel's Conclusion

This study offers a glimmer of hope for those seeking relief from overactive bladder. Vibegron, with its targeted approach and promising results, could be a valuable addition to the oasis of treatment options. Remember, the journey through the desert of overactive bladder can be challenging, but with new and innovative treatments, a more comfortable and confident future is within reach.
Date :
  1. Date Completed 2019-06-19
  2. Date Revised 2019-06-19
Further Info :

Pubmed ID

30661513

DOI: Digital Object Identifier

10.1016/j.eururo.2018.10.006

Related Literature

Article Analysis
・Side Effects of vibegron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.